FDA approved clinical trials of allogeneic CAR-T cell therapy QT-019C for lupus and scleroderma. Savings up to $100 billion, no chemotherapy. Learn about the breakthrough.
Analysis of IMP761 data from Immutep at EULAR 2026: a new class of drugs for treating rheumatoid arthritis without total immunosuppression. Safety, mechanism, and prospects. Read more.
LAG-3 agonist IMP761 has shown clinical efficacy in suppressing T-cells for the first time. Learn about the revolution in treating autoimmune diseases without side effects. Read more.
Genentech proved the efficacy of satralizumab in a rare autoimmune disease. The risk of attacks decreased by 68%, new lesions by 79%. Learn how the first targeted drug fills the niche of empirical therapy.
FDA expanded indications for teplizumab to children from one year. First drug capable of delaying diabetes for years at the preclinical stage. Learn how infusions change the prognosis for infants.
FDA approved Saphnelo subcutaneous pre-filled pens for lupus treatment. Patients can self-administer the drug without visiting a clinic. Learn about the breakthrough in therapy.